June 3, 2020
Kezar Life Sciences, Inc. today announced updated results from the Phase 1b (Ph1b) portion of MISSION, a study testing the safety and tolerability of KZR-616 for people with systemic lupus erythematosus (SLE) and those who also have lupus nephritis.
The drug showed effectiveness in improving seven measures of disease activity. Both of the two patients with lupus nephritis (LN) showed more than a 50 percent reduction in proteinuria, the level of protein in the urine which helps indicate the degree of disease severity. A positive safety and tolerability profile was observed with step-up dosing of KZR-616.
